Patents by Inventor Daniel E. Ryan
Daniel E. Ryan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11947778Abstract: The present disclosure generally relates to navigating a collection of media items. In accordance with one embodiment, in response to receiving an input, a device displays a first view of a collection of media items, including concurrently displaying a representation of a first time period and a representation of a second time period. In accordance with a determination that a current time is associated with a first recurring temporal event: the representation of the first time period includes a first representative media item and the representation of the second time period includes a second representative media item. In accordance with a determination that the current time is associated with a second recurring temporal event, the representation of the first time period includes a third representative media item and the representation of the second time period includes a fourth representative media item.Type: GrantFiled: February 27, 2023Date of Patent: April 2, 2024Assignee: Apple Inc.Inventors: Graham R. Clarke, Simon Bovet, Eric M. G. Circlaeys, Richard R. Dellinger, Lynne Devine, Alan C. Dye, Daniel E. Gobera Rubalcava, Andreas Karlsson, Matthieu Lucas, Johnnie B. Manzari, Nicole R. Ryan, William A. Sorrentino, III, Andre Souza Dos Santos, Gregg Suzuki, Sergey Tatarchuk
-
Publication number: 20240068132Abstract: Nucleation enhancement and/or growth rate improvement of mesophase in pitch compositions derived from hydrocarbon feedstocks can be achieved by: reacting in a reaction zone a blend comprising an isotropic feed and a seeding agent, to produce a reacted pitch having a mesophase content of about 10 vol % to 100 vol %, based on the total volume of the reacted pitch, and a softening point (Tsp) below 400° C.; wherein the seeding agent is about 50 wt % or less, based on the total weight of the blend; wherein the seeding agent has a mesophase content of about 0.01 vol % to 100 vol %, based on the total volume of the seeding agent.Type: ApplicationFiled: November 10, 2021Publication date: February 29, 2024Applicant: ExxonMobil Technology and Engineering CompanyInventors: Manesh Gopinadhan, Stuart E. Smith, Nicole M. Callen, Clarence E. Chase, Kazem V. Edmond, Srinivasan Rajagopalan, Eric B. Sirota, Daniel J. Ryan
-
Patent number: 11884915Abstract: Provided herein are compositions and methods for inducing CRISPR/Cas-based editing of a target nucleic acid (e.g., target DNA or target RNA) in vitro or in a cell, using modified prime editing guide RNAs (pegRNAs) that incorporate one or more chemically-modified nucleotides. The modified pegRNAs disclosed herein may be used to induce Cas-mediated incorporation of one or more nucleotide changes and/or targeted mutagenesis of a target nucleic acid. The nucleotide change can include, e.g., one or more nucleotide changes, an insertion of one or more nucleotides, or a deletion of one or more nucleotides.Type: GrantFiled: September 12, 2022Date of Patent: January 30, 2024Assignee: Agilent Technologies, Inc.Inventors: Daniel E. Ryan, Robert Kaiser, Douglas J. Dellinger
-
Publication number: 20230416733Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.Type: ApplicationFiled: June 9, 2023Publication date: December 28, 2023Inventors: Daniel E. RYAN, Douglas J. DELLINGER, Jeffrey R. SAMPSON, Robert KAISER, Joel MYERSON
-
Patent number: 11851652Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.Type: GrantFiled: March 14, 2022Date of Patent: December 26, 2023Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR, UNIVERSITY and AGILENT TECHNOLOGIES, INC.Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
-
Publication number: 20230340468Abstract: Provided herein are compositions and methods for inducing CRISPR/Cas-based editing of a target nucleic acid (e.g., target DNA or target RNA), or modulating the express of a target nucleic acid, in vitro or in a cell, using modified guide RNAs (gRNAs) that incorporate one or more chemically-modified nucleotides. In some aspects, these modified gRNAs provide superior performance under challenging conditions.Type: ApplicationFiled: September 14, 2022Publication date: October 26, 2023Inventors: Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser
-
Publication number: 20230092393Abstract: Provided herein are compositions and methods for inducing CRISPR/Cas-based editing of a target nucleic acid (e.g., target DNA or target RNA) in vitro or in a cell, using modified prime editing guide RNAs (pegRNAs) that incorporate one or more chemically-modified nucleotides. The modified pegRNAs disclosed herein may be used to induce Cas-mediated incorporation of one or more nucleotide changes and/or targeted mutagenesis of a target nucleic acid. The nucleotide change can include, e.g., one or more nucleotide changes, an insertion of one or more nucleotides, or a deletion of one or more nucleotides.Type: ApplicationFiled: September 12, 2022Publication date: March 23, 2023Inventors: Daniel E. Ryan, Robert Kaiser, Douglas J. Dellinger
-
Patent number: 11535846Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.Type: GrantFiled: March 14, 2022Date of Patent: December 27, 2022Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, AGILENT TECHNOLOGIES, INC.Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
-
Publication number: 20220195425Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.Type: ApplicationFiled: March 14, 2022Publication date: June 23, 2022Applicants: The Board of Trustees of the Leland Stanford Junior University, Agilent Technologies, Inc.Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
-
Publication number: 20220195427Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.Type: ApplicationFiled: March 14, 2022Publication date: June 23, 2022Applicants: The Board of Trustees of the Leland Stanford Junior University, Agilent Technologies, Inc.Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
-
Publication number: 20220195426Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.Type: ApplicationFiled: March 14, 2022Publication date: June 23, 2022Applicants: The Board of Trustees of the Leland Stanford Junior Univerisity, Agilent Technologies, Inc.Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
-
Patent number: 11306309Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.Type: GrantFiled: October 3, 2017Date of Patent: April 19, 2022Assignees: The Board of Trustees of the Leland Stanford Junior University, Agilent TechnologiesInventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
-
Publication number: 20210079389Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.Type: ApplicationFiled: November 24, 2020Publication date: March 18, 2021Inventors: Daniel E. RYAN, Douglas J. DELLINGER, Jeffrey R. SAMPSON, Robert KAISER, Joel MYERSON
-
Patent number: 10900034Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.Type: GrantFiled: December 3, 2015Date of Patent: January 26, 2021Assignee: AGILENT TECHNOLOGIES, INC.Inventors: Daniel E. Ryan, Douglas J. Dellinger, Jeffrey R. Sampson, Robert Kaiser, Joel Myerson
-
Publication number: 20200339980Abstract: The present invention relates to guide RNAs having chemical modifications and their use in CRISPR-Cas systems. The chemically modified guide RNAs have enhanced specificity for target polynucleotide sequences. The present invention also relates to methods of using chemically modified guide RNAs for cleaving or nicking polynucleotides, and for high specificity genome editing.Type: ApplicationFiled: July 15, 2020Publication date: October 29, 2020Inventors: Douglas J Dellinger, Daniel E Ryan, Subhadeep Roy, Jeffrey R Sampson
-
Patent number: 10767175Abstract: The present invention relates to guide RNAs having chemical modifications and their use in CRISPR-Cas systems. The chemically modified guide RNAs have enhanced specificity for target polynucleotide sequences. The present invention also relates to methods of using chemically modified guide RNAs for cleaving or nicking polynucleotides, and for high specificity genome editing.Type: GrantFiled: April 20, 2017Date of Patent: September 8, 2020Assignee: AGILENT TECHNOLOGIES, INC.Inventors: Douglas J Dellinger, Daniel E Ryan, Subhadeep Roy, Jeffrey R Sampson
-
Patent number: 10337001Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.Type: GrantFiled: May 26, 2017Date of Patent: July 2, 2019Assignee: AGILENT TECHNOLOGIES, INC.Inventors: Daniel E. Ryan, Douglas J. Dellinger, Jeffrey R. Sampson, Robert Kaiser, Joel Myerson
-
Publication number: 20180119140Abstract: Provided herein are methods for inducing CRISPR/Cas-based gene regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using modified single guide RNAs (sgRNAs) that enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a modified sgRNA to correct a mutation in a target gene associated with the genetic disease.Type: ApplicationFiled: October 3, 2017Publication date: May 3, 2018Applicants: The Board of Trustees of the Leland Stanford Junior University, Agilent Technologies, Inc.Inventors: Matthew H. Porteus, Ayal Hendel, Joe Clark, Rasmus O. Bak, Daniel E. Ryan, Douglas J. Dellinger, Robert Kaiser, Joel Myerson
-
Patent number: 9932566Abstract: This invention discloses reagents and methods for increasing specificity and efficiency of RNA-guided genome editing.Type: GrantFiled: August 6, 2015Date of Patent: April 3, 2018Assignee: AGILENT TECHNOLOGIES, INC.Inventors: Andrew Kennedy, Daniel E. Ryan
-
Publication number: 20180051281Abstract: The present invention relates to modified guide RNAs and their use in clustered, regularly interspaced, short palindromic repeats (CRISPR)/CRISPR-associated (Cas) systems.Type: ApplicationFiled: May 26, 2017Publication date: February 22, 2018Inventors: Daniel E. Ryan, Douglas J. Dellinger, Jeffrey R. Sampson, Robert Kaiser, Joel Myerson